Waters Corporation filings document operating results, proxy governance, capital-structure changes, material agreements, and corporate events for a NYSE-listed life sciences and diagnostics company. Recent 8-K reports include quarterly and annual results, exhibits furnished with earnings releases, and disclosure tied to the completed combination with BD’s Biosciences and Diagnostic Solutions business.
The company’s SEC record also covers senior unsecured notes issued by Augusta SpinCo Corporation and guaranteed by Waters and certain subsidiaries, pro forma and combined financial information for the acquired business, and definitive proxy materials addressing board oversight, shareholder voting matters, executive compensation, and governance practices.
Waters Corp's SVP, Waters Biosciences, D. Steven Conly, reported direct holdings of 6,030 shares of common stock on October 29, 2026. The reported amount comprises 339 common shares, 117 unvested restricted stock units under the 2020 Equity Incentive Plan and 5,574 unvested restricted stock units under the 2026 Equity-Based Incentive Plan.
He also reported stock appreciation rights and a stock option covering 574 common shares. The 2026-plan RSUs have vesting dates through November 26, 2028, subject to continued service; the option's first vesting installment is February 25, 2027, also subject to continued service.
Waters Corporation (WAT) reported third-quarter 2026 revenue of $1.767 billion, including $871 million of organic revenue and $896 million from acquired Biosciences and Diagnostic Solutions. Organic revenue increased 9% as reported (10% in constant currency) from $800 million. GAAP diluted EPS was $0.82 versus $2.50, reflecting acquisition-related purchase accounting charges, acquisition-related costs and restructuring costs; adjusted EPS rose 21% to $4.10 from $3.40. Operating cash flow was $98 million versus $187 million.
The company raised full-year 2026 revenue guidance by $43 million at the midpoint, to $6.479 billion–$6.497 billion, with organic constant-currency growth of 9.1%–9.7% and adjusted EPS of $14.60–$14.70. Fourth-quarter reported revenue is expected at $1.801 billion–$1.819 billion and adjusted EPS at $4.58–$4.68.
Waters also announced it acquired MOBILion Systems, whose SLIM high-resolution ion mobility technology separates molecules by size, shape and charge; the acquisition is expected to broaden Waters’ entry into proteomics. Management said it would provide its 2027 starting growth framework on the November 3, 2026 earnings call.
Waters Corporation director Heather Knight acquired 57.4100 common stock units on September 30, 2026, in lieu of cash payment of director fees under the company’s 1996 Non-Employee Director Deferred Compensation Plan. The units are convertible into Waters common shares on a one-for-one basis upon distribution on January 1, 2027, pursuant to an election Knight previously made. Her reported direct holdings following the transaction were 1,338 shares.
Waters Corp director Wei Jiang received 57.41 common stock units on September 30, 2026, in lieu of cash payment of director fees under the issuer’s 1996 Non-Employee Director Deferred Compensation Plan. The units convert into Waters common stock on a one-for-one basis upon distribution, which occurs automatically when Jiang’s board service ends. The reported direct position after the transaction was 3,630.16.
WATERS CORP (WAT) filed an initial ownership report for Wu Tong, who serves as SVP Waters Analytical Sciences. This Form 3 establishes Wu Tong as a reporting officer for securities ownership disclosure purposes. The filing reports no transactions or specific holdings at this time and includes a Power of Attorney authorization.
WATERS CORP (symbol WAT) reports an executive leadership change in its Waters Analytical Sciences Division. On August 17, 2026, Robert L. Carpio III notified the company of his decision to resign from his role as Senior Vice President, Waters Analytical Sciences Division to pursue other opportunities, and he relinquished his duties effective August 20, 2026.
Tina Wu, currently Senior Vice President, Waters Materials Sciences Division and President, China, will assume the role of Senior Vice President, Waters Analytical Sciences Division. Ms. Wu joined Waters in June 2026 and has more than two decades of global business-to-business leadership experience across R&D, commercial operations and manufacturing, including over 20 years at DuPont where she led businesses with approximately $1 billion to $2.3 billion in annual net sales and most recently served as Global Vice President, President of DuPont Mobility & Materials since 2021.
Waters Corporation reported sharply higher scale in 2026 following completion of the $12.96 billion acquisition of BD’s Biosciences and Diagnostic Solutions business. For the quarter ended July 4, 2026, total net revenues were $1.65 billion, up from $771 million a year earlier, driven by adding Biosciences and Advanced Diagnostics alongside the legacy analytical instruments business.
Profitability deteriorated as integration-related costs and amortization flowed through. The quarter showed an operating loss of $86 million versus $188 million of operating income a year earlier, with purchased intangibles amortization of $244 million and restructuring charges of $49 million. Net loss was $136 million for the quarter and $208 million for the first half, compared with net income of $147 million and $268 million in the prior-year periods.
The balance sheet expanded significantly: total assets rose to $24.75 billion, including $9.42 billion of goodwill and $8.52 billion of intangible assets. Debt increased to $5.09 billion, mainly from new Senior Notes and a SpinCo term loan used in the transaction, while cash and cash equivalents stood at $539 million. Waters also implemented a workforce reduction affecting about 3% of employees, recording $52 million of severance-related restructuring costs.
Waters Corp director Christopher A. Kuebler reported exercising stock options for 3,626 shares of common stock on August 6, 2026, at 136.4300 per share.
On the same date he sold 3,626 common shares at 397.9400 per share in a transaction described as a sale in open market or private transaction.
Waters Corporation reported strong top-line growth for the quarter ended July 4, 2026, with net revenue of $1.645 billion, up from $771 million a year earlier. Organic revenue was $828 million versus $771 million, representing 7% organic reported growth and 9% in constant currency, while the recently acquired Biosciences and Diagnostic Solutions businesses contributed $817 million. By division, Analytical Sciences delivered $669 million, Biosciences $368 million, Advanced Diagnostics $521 million, and Materials Sciences $87 million.
Despite this growth, acquisition-related purchase accounting charges and other costs led to a GAAP diluted loss per share of $(1.39), compared with EPS of $2.47 in the prior-year quarter. Adjusted diluted EPS rose to $3.05 from $2.95. Operating cash flow for the quarter was $200 million and adjusted free cash flow was $202 million. The company raised full-year 2026 guidance, now expecting total revenue of $6.415–$6.476 billion and adjusted EPS of $14.45–$14.65, implying 7–9% organic constant currency revenue growth. Debt increased to $5.086 billion at July 4, 2026, reflecting financing for recent acquisitions, while total stockholders’ equity rose to $15.195 billion.